• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2012 - Product Image

Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2012

  • ID: 2199773
  • July 2012
  • Region: Saudi Arabia
  • 105 pages
  • Business Monitor International

The Saudi Arabia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Saudi Arabia's pharmaceuticals and healthcare industry.

BMI View: The Saudi Arabian government said it will increase its healthcare budget for 2012 by 26%.

Though BMI remains slightly more conservative in our growth forecasts, we think the government’s investment in the sector is very positive for the healthcare industry. Furthermore, the announcement and allocation of various tenders and contracts for health facility construction and fitting helps to dispel our fear that real public healthcare expenditure would not live up to the political rhetoric.

Headline Expenditure Projections
- Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.96bn (US$5.06bn) in 2012; +13.6% in local currency and US dollar terms. Forecast up significantly from Q212 based on new historic data.

- Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.23bn (US$24.36bn) in 2012; +16.0% in local currency and US dollar terms. READ MORE >

Executive Summary 5

SWOT Analysis 7

Saudi Arabia Pharmaceuticals And Healthcare SWOT 7

Saudi Arabia Political SWOT 8

Saudi Arabia Economic SWOT 9

Saudi Arabia Business Environment SWOT 9

Pharmaceutical Risk/Reward Ratings 10
Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q312 11

Rewards 13

Risks 14

Market Overview – Saudi Arabia 16

Regulatory Regime 17

Regulatory Developments 18

Regional Regulatory Developments 19

Free Trade Agreements 20

Intellectual Property Developments 20

IP Deficiencies 21

Counterfeit Drugs 23

OTC Drug Market 24

Pricing Regime 24

Reimbursement Regime 25

Pricing System Reform 25

Tendering Procedures 26

Industry Trends And Developments 27

Epidemiology 27

Public Health Developments 28

Healthcare Sector 29

Private Healthcare Sector 30

Public And Private Healthcare Developments 31

Healthcare Professionals 33

Primary Healthcare Provision 34

Secondary Healthcare Provision 34

Health Insurance 35

Health Insurance Developments 36

Research & Development 38

Medical Device Sector 39

Medical Device Developments 40

Industry Forecast Scenario 41

Pharmaceutical Market Forecast 41
Table: Pharmaceutical Sales, 2008-2016 43

Key Growth Factors – Industry 44
Table: Overall Healthcare Expenditure, 2008-2016 45
Table: Government Healthcare Expenditure, 2008-2016 46
Table: Private Healthcare Expenditure, 2008-2016 46

Key Growth Factors – Macroeconomic 47
Table: Saudi Arabia GDBP By Expenditure, Real Growth, 2008-2016 51

Prescription Drug Market Forecast 53
Table: Prescription Drug Sales, 2008-2016 54

Patented Drug Market Forecast 55
Table: Patented Drug Sales, 2008-2016 56

Generic Drug Market Forecast 57
Table: Generic Drug Sales, 2008-2016 58

OTC Medicine Market Forecast 59
Table: OTC Medicine Sales, 2008-2016 60

Medical Device Market Forecast 61
Table: Medical Device Sales, 2008-2016 62

Pharmaceutical Trade Forecast 63
Table: Pharmaceutical Trade, 2008-2016 65

Other Healthcare Data Forecasts 66

Key Risks To BMI Forecasts 67

Competitive Landscape 68

Pharmaceutical Industry 68

Foreign Industry 68

Domestic Industry 70

Regional Harmonisation 72

Pharmaceutical Company Developments 73

Pharmaceutical Distribution Sector 74

Pharmaceutical Retail Sector 74

Company Profiles 76

Saudi Pharmaceutical Industries And Medical Appliances Corp (SPIMACO) 76

Saudi Arabian Japanese Pharmaceutical (SAJA) 79

TABUK Pharmaceutical Manufacturing 81

Jamjoom Pharma 83

GlaxoSmithKline 85

Novartis 87

Merck & Co 89

Pfizer 91

Sanofi 93

Demographic Outlook 95
Table: Population By Age Group, 1990-2020 (‘000) 96
Table: Population By Age Group, 1990-2020 (% of total) 97
Table: Key Population Ratios, 1990-2020 98
Table: Rural/Urban Population Spliy, 1990-2020 98

Glossary 99

BMI Methodology 101

How We Generate Our Pharmaceutical Industry Forecasts 01

Pharmaceuticals Risk/Reward Ratings Methodology 02

Ratings Overview 02
Table: Pharmaceutical Ris/Reward Indicators 03

Weighting 04
Table: Weighting Of Components 04

Sources 04

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos